Every 10-Q that EBR SYS INC (EBRCZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EBRCZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EBRCZ filings page.
EBR Systems, Inc. reported rapid early commercialization of its WiSE CRT System but remains deeply loss-making and flagged substantial doubt about its ability to continue as a going concern. Net sales for the quarter ended June 30, 2026 rose to $2.6 million from $0.2 million a year earlier, driven by 46 commercial implants at 23 U.S. hospitals; six‑month net sales were $5.0 million on 87 implants at 29 hospitals. The company posted a quarterly net loss of $17.5 million and a six‑month net loss of $34.5 million, with operating cash outflow of $37.4 million.
Cash, cash equivalents and marketable securities were $86.9 million at June 30, 2026, boosted by June equity raises that added roughly $76 million of net financing cash and increased common shares outstanding to about 75.3 million. EBR has $41.8 million of debt due in 2027 and a minimum liquidity covenant of $2.5 million; management warns covenant pressure and ongoing losses create substantial doubt about its 12‑month liquidity unless it completes an additional related‑party placement and refinances its debt.
EBR Systems, Inc. reported its first meaningful commercial quarter, with Q1 2026 revenue of $2.4M from WiSE CRT System implants but a net loss of $17.1M and a gross margin of 7.8%. The company completed 41 commercial implants across 19 U.S. hospitals.
Cash, cash equivalents and marketable securities totaled $30.9M as of March 31, 2026, against noncurrent debt of $41.8M and negative operating cash flow of $20.3M for the quarter. Management discloses “substantial doubt” about EBR’s ability to continue as a going concern without raising additional capital.
Operating expenses rose sharply as EBR scaled commercialization, with research and development at $6.4M and selling, general and administrative expenses at $9.9M. Adjusted EBITDA was a loss of $15.1M, underscoring the need to grow procedure volumes or secure new funding to support ongoing operations and service upcoming debt maturities.
EBR Systems, Inc. reported Q3 2025 results as it begins commercial rollout of its WiSE CRT System following FDA approval on April 11, 2025. Revenue reached $512,093, generating gross profit of $223,722. Operating expenses were $12.1 million (R&D $6.24 million; SG&A $5.86 million), resulting in an operating loss of $11.88 million and a net loss of $12.19 million for the quarter. For the nine months, revenue was $681,797 with a net loss of $34.71 million.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $70.40 million, including cash and equivalents of $12.64 million and short-term marketable securities of $55.72 million. Notes payable, net, were $40.73 million with maturity in 2027. Inventory increased to $11.17 million as production scaled. Stockholders’ equity was $38.65 million. Shares outstanding were 449,889,450 as of September 30, 2025; the company reported 449,994,658 outstanding as of November 12, 2025.